The FDA’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee has voted in favor of ...
The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...
Peter Voorhees, MD, discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at the IMS conference. Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG ...
Gurbakhash Kaur, MD, an assistant professor of internal medicine at Mount Sinai Health System, discusses the shifting role of autologous stem cell transplant (ASCT) in an era incr ...
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...
Cure is defined as 5 years in complete remission without any anti-myeloma therapy, timed from treatment end rather than from initial response while still on treatment. Eligibility requires ≥4 ...
The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML ...
FDA labeling now reports a 49.7-month median DOR in TKI-naive advanced ROS1+ NSCLC from TRUST-I, based on 51-month median ...
Shubham Pant, MD, MBBS, discusses the rapidly growing pipeline of RAS-directed agents for patients with pancreatic cancer, building on the momentum of the recent FDA approval of daraxonrasib (Rasonque ...
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...
Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results